M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout Pharmaceutical TechnologyJ J strikes its deal with Sail as the in vivo CAR-T space becomes increasingly crowded, with several big pharma players betting on the class.OncologyRead full story pharminent July 31, 2026 (Last updated: August 3, 2026) Pharmaceutical Technology J J strikes its deal with Sail as the in vivo CAR-T space becomes increasingly crowded, with several big pharma players betting on the class. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Amgen’s Repatha Wins Positive CHMP Opinion for Preventing First Heart Attacks and StrokesNext: Outlook Therapeutics Secures FDA Approval for LYTENAVA Related Stories M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026 M&A / Deals Argenx deepens immuno expertise with $2.2B Forte Biosciences buy pharminent July 27, 2026
